Hematologic Oncology

In recent years, cellular immune therapies such as chimeric antigen receptor T-cell therapy have significantly improved response rates for various hematological malignancies.

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss what motivated them to continue working toward improvements in the leukemia field, even when outcomes were dismal and treatment options were scarce.

Matthew J. Frigault, MD, discusses the findings from a phase 1 trial investigating the safety and efficacy of CART-ddBCMA in patients with multiple myeloma in whom all previous lines of treatment had failed and shares additional research opportunities for the CAR T-cell therapy.

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss the challenges that accompanied the lack of progress in leukemia treatment when they began their fellowships and express their excitement about encouraging developments that have since emerged in the arena.

Elotuzumab plus pomalidomide and dexamethasone demonstrated a significant improvement in overall survival compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma who previously received treatment with lenalidomide and a proteasome inhibitor.

The FDA has lifted a partial clinical hold on the open-label, dose-escalating phase 1/2 TakeAim Lymphoma trial investigating the safety and efficacy of emavusertib in patients with relapsed or refractory B-cell malignancies.

Shared insight on clinical trials investigating the frontline use of thrombopoietin receptor agonists in patients with immune thrombocytopenia.

The combination of lenalidomide and rituximab demonstrated durable safety and efficacy that was comparable to that achieved with rituximab plus chemotherapy in previously untreated patients with follicular lymphoma, according to 6-year data from the phase 3 RELEVANCE trial.

A brief review of how the management of patients with immune thrombocytopenia has been impacted by the COVID-19 pandemic.

The FDA has approved betibeglogene autotemcel (Zynteglo) for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Won Seog Kim, MD, PhD, discusses the potential clinical role of Anbalcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma and the continued evolution of CAR T-cell therapy.

Raul Cordoba, MD, PhD, discussed the efficacy and safety findings from cohort 4 of the EPCORE NHL-2 trial, the benefits observed with epcoritamab monotherapy in patients who did not proceed to transplant, and what the addition of epcoritamab to R-DHAX/C could mean for patients with relapsed/refractory DLBCL.

Saad Z. Usmani, MD, MBA, FACP, discusses key efficacy findings that support the use of teclistamab in patients with relapsed/refractory multiple myeloma who have had prior exposure to BCMA-targeted agents.

Following their review of available treatment for steroid refractory chronic GVHD, experts consider how they would optimally select and sequence therapy.

Comprehensive discussion on each of the 3 standard-of-care treatment options for patients with steroid refractory chronic GVHD.

Single-agent tolinapant generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma, according to data from the phase 2 ASTX660-01 trial.

Jean-Marie Michot, MD, discusses the methods and rationale for the CC-99282-NHL-001 study.

Experts consider how treatment duration can impact patient outcomes in immune thrombocytopenia and discuss discontinuation of TPO-Ras.

Comprehensive discussion on nuancing the risk of thrombosis with thrombopoietin receptor agonists in immune thrombocytopenia.

Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to continue to work toward progress in the field even when treatment outcomes were dismal. They also share their experiences with being women in their chosen career paths, such as how their gender has influenced their professional and personal decisions, as well as how they interact with and support other female colleagues.

The panelists share their approach to the treatment and work-up of patients who require salvage therapy.

An overview of the frontline treatment armamentarium for patients diagnosed with chronic graft versus host disease.

Shifting their focus to chronic graft versus host disease, panelists emphasize the importance of early identification and diagnosis.

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

Amrita Krishnan, MD, discusses emerging data on bispecific antibodies, the exploration of the antibody-drug conjugate belantamab mafodotin, and the challenges of delivering CAR T-cell therapy in the right setting to the appropriate patients with multiple myeloma.